Avatar

The Future of CAR T Therapies in Myeloma in 2018

By Nina Shah 3 Videos
06/2018
0 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
City of Hope

How the Experts Treat Hematologic Malignancies

Thu, Mar 21, 2019
Indy Hematology Review

16th Annual Indy Hematology Review

Sat, Mar 9, 2019
08:14
2018 Pan Pacific Lymphoma Conference

Evolution of Myeloma Induction Regimens

Feat. S. Holstein
13:22
Parameswaran Hari

CAR T and NK Cell Therapy in Myeloma

15:46
Society of Hematologic Oncology Sixth Annual Meeting

Myeloma State of the Art Update: Bone Disease, MRD Assessment, How to Ma...

Feat. S. Lonial
09:49
Nina Shah

Maximizing the Initial Gains in Myeloma Therapy: Consolidation and Maint...

15:01
Krina Patel

Clinical Trials in Myeloma in 2018

10:29
Society of Hematologic Oncology Sixth Annual Meeting

Next Questions in Myeloma: Biology, Smoldering Myeloma, High-risk, MRD, ...

Feat. S. Jagannath
19:40
Peter Voorhees

Approach to the Patient with Refractory & Multiple Relapsed Multiple Mye...

12:31
Indy Hematology Review

What's New in Immunotherapy and Genomics in Multiple Myeloma?

Feat. K. Anderson
15:10
Ajay Nooka

Early Relapse: Choosing Among Different Second Line Regimens in Myeloma

15:30
Parameswaran Hari

Refractory and Relapsing Myeloma - When to Treat and Options Available

09:45
2018 Pan Pacific Lymphoma Conference

CAR T-cell Toxicities and Team Managment

Feat. S. Blumel
13:29
Helen Heslop

CAR T-cell Therapy for Hematologic Malignancies Other Than CD19

10:37
Krina Patel

How Do We Make Responses Durable in Multiple Myeloma?

17:46
Dana-Farber Cancer Institute

Relapse Refractory Myeloma and Novel Treatments

Feat. N. Raje
06:22
Parameswaran Hari

Treating Refractory & Relapsing Myeloma: Current Trends and Recommendati...

09:00
Maria-Victoria Mateos

FDA Approves Once-Weekly Carfilzomib Regimen for Myeloma

14:42
Society of Hematologic Oncology Sixth Annual Meeting

What Will The Future Hold for Myeloma Treatment CARTs vs BiTES?

Feat. R. Orlowski
11:50
C. Ola Landgren

Aiming for Minimal Residual Disease Negative Status in all Myeloma Patients

15:44
Society of Hematologic Oncology Sixth Annual Meeting

The Role of ASCT In The Era of Modern MM Therapy

Feat. P. Voorhees
03:33
Krina Patel

The Future in Multiple Myeloma: BiTE, CAR T, PI, & IMID